Bladder EpiCheck®

Bladder EpiCheck^® provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors. The test analyzes subtle disease-specific changes in DNA methylation markers, allowing for the detection of 91%¹ of the high-risk (non Ta-LG) cancers. High risk cancers² are important to catch as they are aggressive and most likely to progress to invasive cancer if not treated immediately. Bladder EpiCheck^® demonstrated Negative Predictive Value (NPV) of 99%¹ for high-risk cancer, meaning that when receiving a negative Bladder EpiCheck^® result, there is 99%¹ chance that no high-risk cancer is present. Bladder EpiCheck^® can be used in a surveillance regimen to increase confidence in detection of recurrence and/or to reduce amount of cystoscopies.

Bladder EpiCheck^® provides you with

• 99 % Negative Predictive Value
• Objective and operator independent test results with excellent high-grade sensitivity and specificity (91 % and 84 %)
• Simple test result interpretation (pos/neg and EpiScore from 0-100)
• Potential reduction in unnecessary cystoscopies resulting in reduced patient and financial burden

References

1. Laukhtina et al. Eur Urol Oncol 2021 Dec;4(6):927-942; and corrigendum at Eur Urol Oncol. 2022 Jan 19;S2588-9311(22)00004-9. doi: 10.1016/j.euo.2022.01.003
2. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis

Bladder EpiCheck^® Brochure (EN)

More information about Bladder EpiCheck® can be found from Nucleix Ltd website: https://www.nucleix.com/bladder-epicheck/